Research programme: Alzheimer's disease therapeutics - Oligomerix

Drug Profile

Research programme: Alzheimer's disease therapeutics - Oligomerix

Latest Information Update: 06 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OLIGOMERIX
  • Class Antibodies; Small molecules
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 02 May 2016 Oligomerix receives Direct to phase II SBIR grant from National Institute of Aging, National Institutes of Health for small molecule drug development in Alzheimer's disease
  • 30 Jun 2014 Research programme: Alzheimer's disease therapeutics - Oligomerix is available for licensing as of 30 Jun 2014. www.oligomerix.com
  • 30 Jun 2014 Preclinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top